title: Effects of ribosomal protein l39-L on the drug resistance mechanisms of lung cancer A549 cells.
abstract: BACKGROUND
  Cancer is a major threat to the public health whether in developed or in developing countries. As the most common primary malignant tumor, the morbidity and mortality rate of lung cancer continues to rise in recent ten years worldwide. Chemotherapy is one of the main methods in the treatment of lung cancer, but this is hampered by chemotherapy drug resistance, especially MDR. As a component of the 60S large ribosomal subunit, ribosomal protein L39-L gene was reported to be expressed specifically in the human testis and human cancer samples of various tissue origins.
  
  
  METHODS
  Total RNA of cultured drug-resistant and susceptible A549 cells was isolated, and real time quantitative RT-PCR were used to indicate the transcribe difference between amycin resistant and susceptible strain of A549 cells. Viability assay were used to show the amycin resistance difference in RPL39-L transfected A549 cell line than control vector and null-transfected A549 cell line.
  
  
  RESULTS
  The ribosomal protein L39-L transcription level was 8.2 times higher in drug-resistant human lung cancer A549 cell line than in susceptible A549 cell line by quantitative RT-PCR analysis. The ribosomal protein L39-L transfected cells showed enhanced drug resistance compared to plasmid vector-transfected or null-transfected cells as determined by methyl tritiated thymidine (3H-TdR) incorporation.
  
  
  CONCLUSIONS
  The ribosomal protein L39-L gene may have effects on the drug resistance mechanism of lung cancer A549 cells.
authors.affiliation: Intensive Care Unit of Affiliated Hospital of Jining Medical University, Jining, China E-mail : 1392144@163.com.
authors.forename: Hong-Sheng
authors.initials: HS
authors.lastname: Liu
authors.forename: Wen-Bin
authors.initials: WB
authors.lastname: Tan
authors.forename: Ning
authors.initials: N
authors.lastname: Yang
authors.forename: Yuan-Yuan
authors.initials: YY
authors.lastname: Yang
authors.forename: Peng
authors.initials: P
authors.lastname: Cheng
authors.forename: Li-Juan
authors.initials: LJ
authors.lastname: Liu
authors.forename: Wei-Jie
authors.initials: WJ
authors.lastname: Wang
authors.forename: Chang-Liang
authors.initials: CL
authors.lastname: Zhu
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics; D003906:Developing Countries; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D006146:Guanidines / Q000494:pharmacology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D012269:Ribosomal Proteins / Q000096:biosynthesis / Q000235:genetics*; D054683:Ribosome Subunits, Large, Eukaryotic; D014162:Transfection
chemical_list: D000970:Antineoplastic Agents; D006146:Guanidines; C471571:RPL39L protein, human; D012269:Ribosomal Proteins; C065212:amycin A